Buradasınız

Optik Koherens Tomografi ile Saptanan Perifoveal Çanaklaşma Antimalaryal İlişkili Makulopatinin Erken Bulgusu Olabilir

Perifoveal Cupping Detected by Optical Coherence Tomography May Represent an Early Sign of Antimalarial-Associated Maculopathy

Journal Name:

Publication Year:

Abstract (2. Language): 
Objective: To evaluate foveal structural changes by spectral domain optical coherence tomography (Sd-OCT) in patients receiving antimalarials. Materials and Methods: The study was designed as an observational case-control study. Twenty eight patients receiving chloroquine (CQ) or hyd-roxychloroquine (HCQ) were evaluated clinically using Sd-OCT and automated visual fields. Twenty age-matched subjects serving as controls were imaged with Sd-OCT. Results: The mean age of the patients was 34.2 years (ranged from 22 to 40 years). All patients were female. The control subjects were included twenty females (mean age: 31.4; ranged from 19 to 42 years). Eighteen patients receiving anti-malarial drugs had mild retina pigment epithelium (RPE) changes and perifoveal cupping detected by Sd-OCT without visual field defect. In the rest of patients in and the controls, perifoveal retinal thicknesses as well as central foveal thicknesses did not show any significant difference. These cases had not perifoveal cupping and visual field defect. The mean central foveal thicknesses in the patients with perifoveal cupping and without perifoveal cupping were 219.57±20.12 |im and 222.42±24.02 |im, respectively. The mean central foveal thickness, as determined by OCT, was 221.13±25.44 (range 201-248 |im) in the patients and 218.96±22.02 |im (range 189-239 |im) in controls. The difference between the groups was not statistically significant (p=0.7). Conclusion: Perifoveal cupping, in the other words, perifoveal retinal thinning may be a predictor for impending antimalarial related maculopathy.
Abstract (Original Language): 
Amaç: Antimalaryal ilaç kullanan hastalarda spectral domain optik koherens tomografi kullanılarak foveal yapısal değişiklikleri değerlendirmek. Gereç ve Yöntem: Çalışma bir gözlemsel vaka-kontrol çalışması olarak kurgulandı. Klorakin veya hidroksiklorakin alan 28 hasta ile benzer demografik özelliklere sahip 20 kontrol olgusu spektral domain optik koherens tomografi ve otomatize görme alanı ile klinik olarak değerlendirilerek bulgu¬lar karşılaştırıldı. Bulgular: Hastaların yaş ortalaması 34.2 yaş (22 to 40 yaş) idi. Tüm hastalar kadındı. Kontrol olgularının tümü kadın olup yaş ortalaması 31.4 yaş (19-42) idi. Antimalaryal ilaç alan hastaların onsekizinde görme alanı defekti bulunmadan hafif retina pigment epitel değişikliği ve optik koherens tomografi ile saptanan perifoveal çanaklaşma mevcuttu. Geri kalan hastalarda ve de kontrol grubundaki bireylerde santral foveal kalınlıklar gibi perifoveal retinal kalınlıklar da herhangi bir anlamlı fark göstermedi. Bu olgularda perifoveal çanaklaşma ve görme alanı defekti saptanmadı. Peri-foveal çanaklaşma olan ve çanaklaşma olmayan hastalardaki santral foveal kalınlıklar sırasıyla 219.57±20.12 |im ve 222.42±24.02 |im idi. Optik koherens tomografi ile saptanan ortalama santral foveal kalınlık hasta grubunda 221.13±25.44 |im_(201-248 |im aralığında) ve kontrol grubunda 218.96±22.02 |im (189-239 |im aralığında) idi. Gruplar arasındaki farklılık istatistiksel olarak anlamlı değildi (p=0.740). Sonuç: Perifoveal çanaklaşma,diğer değişle perifoveal retinal incelme antimalaryal ile ilişkili makulopatinin gelişiyor olduğunu gösteren bir prediktor olabilir.
238-242

REFERENCES

References: 

1. Fyodorov I, Sturm PF, Robertson WW Jr. Compression-plate fixation of femoral shaft fractures in children aged 8 to 12 years. J Pediatr Orthop 1999; 19: 578-81.
2. Yam JC, Kwok AK.Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304.
3. Wetterholm DH, Winter FC. Histopathology of chloroquine
retinal toxicity. Arch Ophthalmol 1964; 71: 82-7.
4. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112: 528-34.
5. Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 1993; 23: 62-7.
6. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hyd-roxychloroquine retinopathy: a report by the American Aca¬demy of Ophthalmology. Ophthalmology 2002; 109: 1377-82.
7. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991; 254: 1178-81.
8. Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine re-tinopathy similar to multifocal electroretinography, fundus au-tofluorescence and near-infrared autofluorescence. Br J Opht-
halmol 2009; 93: 1444-7.
9. Rodriguez-Padilla JA, Hedges TR 3rd, et al. High-speed ultra-high-resolution optical coherence tomography findings in hyd-roxychloroquine retinopathy. Arch Ophthalmol 2007; 125:
775-80.
241
Fırat Tıp
Dergis
i 2012; 17(4): 238-242
10. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis
Sci 2006; 47: 3531-8.
11. Kellner U, Kellner S, Weinitz S. Chloroquine retinopathy: lipofuscin- and melanin-related fundus autofluorescence, opti¬cal coherence tomography and multifocal electroretinography. Doc Ophthalmol 2008; 116: 119-27.
12. Fung AE, Samy CN. Optical coherence tomography findings in hydroxychloroquine and chloroquine-associated maculo-pathy. Retinal Cases & Brief Reports 2007; 1: 128-30.
Turgut and Koca
13. Fontaine F, Rougier MB. Optical coherence tomography in hydroxychloroquine retinopathy: two observational case re¬ports. Retinal Cases & Brief Reports 2007; 1: 131-3.
14. Korah S, Kuriakose T. Optical coherence tomography in a patient with chloroquine-induced maculopathy. Indian J Opht-
halmol 2008; 56: 511-3.
15. Turgut B, Turkcuoglu P, Koca SS, Aydemir O. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 2009; 28: 607-9.

Thank you for copying data from http://www.arastirmax.com